



CERTIFICATE



This is to certify that the company

ZytoVision GmbH

Fischkai 1
27572 Bremerhaven
Germany

with the organizational units/sites as listed in the annex

has implemented and maintains a **Quality Management System**.

Scope of certification:

Design and development, manufacturing and distribution of in-vitro diagnostic medical devices used in the diagnosis of genetic and chromosomal aberrations, gene expression and associated viral and microbial infections.

- **BRA, CND, JPN**

Through an audit, documented in a report, performed by DQS Medizinprodukte GmbH, it was verified that the management system fulfills the requirements of the following standard:

ISO 13485 : 2016


including applicable country-specific regulatory requirements, as indicated below the scope (full references of abbreviations are listed in the annex)

Certificate registration no.	31624748 MDSAP16
Certificate unique ID	1000303993
Effective date	2026-04-29
Expiry date	2028-08-27
Frankfurt am Main	2026-04-29



DQS Medizinprodukte GmbH

Heinrich von Mettenheim
Managing Director





Annex to certificate
Certificate registration No.: 31624748 MDSAP16
Certificate unique ID: 1000303993
Effective date: 2026-04-29

ZytoVision GmbH

Fischkai 1
27572 Bremerhaven
Germany

Audited site

ZytoVision GmbH
Fischkai 1
27572 Bremerhaven
Germany

REPs FEI No.: site scope and country-specific requirements

Design and development, manufacturing and distribution of in-vitro diagnostic medical devices used in the diagnosis of genetic and chromosomal aberrations, gene expression and associated viral and microbial infections.
- BRA, CND, JPN
REPs FEI No.: F008416



Annex to certificate
Certificate registration No.: 31624748 MDSAP16
Certificate unique ID: 1000303993
Effective date: 2026-04-29

ZytoVision GmbH

Fischkai 1
27572 Bremerhaven
Germany

Full references of country-specific requirements of MDSAP participating Regulatory Authorities

Abbreviation	Jurisdiction	Reference
AUS	Australia	(a) Therapeutic Goods (Medical Devices) Regulations 2002, Schedule 3, Part 1 – Full Quality Assurance Procedure (b) Therapeutic Goods (Medical Devices) Regulations 2002, Schedule 3, Part 4 – Production Quality Assurance Procedure
BRA	Brazil	RDC ANVISA n. 665/2022 RDC ANVISA n. 551/2021 RDC ANVISA n. 67/2009
CND	Canada	Medical Devices Regulations – Part 1- SOR 98/282 Medical Devices Regulations – Part 1.1 – SOR 98/282 (as applicable)
JPN	Japan	MHLW Ministerial Ordinance 169, Article 4 to Article 68 Japan PMD Act (as applicable)
USA	United States	(a) 21 CFR Part 803 (b) 21 CFR Part 806 (c) 21 CFR Part 807 (d) 21 CFR Part 820 (e) 21 CFR Part 821